Market Intelligence, Clinical Progress, and High-Purity Reagents for Allergy, CNS, and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HRH1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Cell Line Tool | HRH1 Full-Length Lentiviral Particle. High-titer, sequence-verified ORF. Pseudotyped for broad tropism. Endotoxin controlled. | View HRH1 Products |
| Gene Delivery | HRH1 Promise-ORF Lentivirus (NM_000861). CMV promoter-driven full-length ORF with Puromycin selection marker. HEK293 packaging, titer >10^8 TU/mL. | View HRH1 Products |
| Stable Cell Line | HRH1 Lentivirus Transduction Service. Calcium flux-validated stable pool, Endotoxin controlled. | View HRH1 Products |
| Benchmark Ab | Anti-HRH1 Monoclonal Antibody. Research-grade recombinant binder for flow cytometry and cellular assay validation. Endotoxin <1EU/ug. | View HRH1 Products |
| Validator | HRH1 siRNA Set (3 unique sequences). Gene-specific knockdown for target specificity and off-target mitigation controls. | View HRH1 Products |
| Related Target A | HRH2 (Histamine H2 Receptor). Subfamily counter-screening to confirm peripheral selectivity and avoid gastric off-target effects. | View HRH2 Products |
| Related Target B | HRH3 (Histamine H3 Receptor). CNS off-target liability assessment and dual-target strategy. | View HRH3 Products |
| Related Target C | HRH4 (Histamine H4 Receptor). Immuno-oncology and inflammation pathway node for synergistic combination rationale. | View HRH4 Products |
Critical Assay Requirements
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native 7-TM Conformation & Signaling | Lentivirus-based stable cell lines preserving native glycosylation, topology and Gq signaling (calcium flux). HEK293/Ga16 lines for robust signal. |
| Subfamily Selectivity (HRH1 vs HRH2/3/4) | Parallel lentivirus and recombinant panels for all four histamine receptor subtypes; sequence-verified, endotoxin <1 EU/ug. |
| Species Cross-Reactivity for Toxicology | Human/Mouse/Cyno/Rat HRH1 ORFs available with strict sequence fidelity; enables parallel safety pharmacology. |
| Signal Pathway Bias Detection | Cell lines compatible with Calcium Flux (FLIPR) and cAMP (GloSensor) assays; Gq vs Gs pathway discrimination. |
| BBB Penetration Modeling | Cyno/Rat ortholog proteins for comparative binding affinity; predictive of CNS vs peripheral exposure. |
| Lack of Cellular Controls | Validated siRNA sets plus reference-grade anti-HRH1 antibody enable knockdown verification and assay calibration. |
| False Positives / Off-Target Pharmacology | Full-length HRH1 stable cell lines support functional second-messenger readouts (IP1, cAMP) alongside orthogonal binding confirmation. |
Live HRH1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials (Allergic Indications)
- CNS & Insomnia Trials
- Latest Resistance & Mechanism Research
- Recent Patent Filings (Inverse Agonists)
Key Genetic Variants
Known missense variants in HRH1 (dbSNP: rs2067466, rs7651620) and a somatic mutation in a colorectal cancer sample (rs1370695377) have been reported (UniProt P35367). These variants may influence drug binding and patient response, highlighting the need for genetically diverse assay panels.
Global Clinical Landscape & Future Outlook
The race for next-generation HRH1 therapeutics is shifting from sedating first-generation antagonists toward highly peripherally selective, long-residence-time inverse agonists. While allergic rhinitis and urticaria remain the largest indications, emerging R&D is exploring HRH1 modulation in neuroinflammatory disorders and tumor microenvironment (TME) regulation, where histamine signaling influences myeloid-derived suppressor cell (MDSC) activity. Current R&D intensity focuses on CNS-penetrant variants for sleep/cognitive disorders and peripherally-restricted molecules for allergy/autoimmune indications to avoid sedation liability. Emerging preclinical data positions HRH1 blockade as a TME modulator, potentially synergizing with immune checkpoint inhibitors by reducing MDSC recruitment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Inverse Agonist) | Sanofi, Bayer, GSK, Almirall, Uriach (Rupatadine), Viatris | Allergic Rhinitis, Urticaria, Pruritus | Subfamily selectivity panel (HRH1 vs HRH2/3/4) using full-length stable cell lines; sequence-verified orthologs. |
| Topical / Nasal / Ophthalmic | Alcon, Novartis, Glenmark, Bausch + Lomb | Conjunctivitis, Allergic Dermatitis | Receptor internalization and recycling kinetics on live HRH1-expressing cells; high-titer lentivirus for stable transduction. |
| CNS-Sparing / CNS-Targeted Antagonist | FAES Farma (Bilastine), UCB (Levocetirizine), Bioprojet, Palatin | Chronic Urticaria, Allergic Rhinitis (pediatric), Insomnia, Cognitive Disorders | Functional cAMP/calcium flux assays to differentiate inverse agonism; BBB permeability prediction using human/cyno/rat orthologs. |
| Combination Therapy (Immuno-Oncology) | Incyte, Regeneron | Oncology (TME Modulation) | Stable cell lines for immune co-culture (HRH1+ lentivirus lines); MDSC recruitment assays. |
| Biased Ligand | Academic Consortia | Anti-pruritic (Non-sedating) | Pathway bias profiling (calcium vs cAMP) to separate Gq from β-arrestin signaling. |
Related Targets & Strategy
Based on HRH1 indication expansion, the following associated targets are recommended:
- HRH3: Dual modulation for CNS indications (wakefulness/sleep); package as "arousal disorder research panel".
- HRH4: Chemotaxis in inflammation and tumor immunity; HRH1/HRH4 dual blockade may produce superior anti-inflammatory effects for immuno-oncology clients.
- CYSLTR1: Leukotriene receptor; combined with H1R blockers or dual-target drugs for severe allergic asthma.